|
USA-NY-SALEM Azienda Directories
|
Azienda News:
- Contribution of Pretomanid to Novel Regimens Containing Bedaquiline . . .
Novel regimens combining bedaquiline and pretomanid with either linezolid (BPaL regimen) or moxifloxacin and pyrazinamide (BPaMZ regimen) shorten the treatment duration needed to cure tuberculosis (TB) in BALB c mice compared to that of the first-line regimen and have yielded promising results in in …
- [PDF] Contribution of Pretomanid to Novel Regimens Containing . . .
In 3 different mouse models, pretomanid contributed significantly to the efficacy of the BPaMZ and BPaL regimens, including restricting the selection of bedaquiline-resistant mutants and reduced the proportion of mice relapsing compared to that for BMZ treatment alone Novel regimens combining bedaquiline and pretomanid with either linezolid (BPaL regimen) or moxifloxacin and pyrazinamide
- Contribution of Pretomanid to Novel Regimens Containing Bedaquiline . . .
Novel regimens combining bedaquiline and pretomanid with either linezolid (BPaL regimen) or moxifloxacin and pyrazinamide (BPaMZ regimen) shorten the treatment duration needed to cure tuberculosis (TB) in BALB c mice compared to that of the first-line regimen and have yielded promising results in initial clinical trials
- Pretomanid in drug-resistant tuberculosis: a profile of its use
Pretomanid, a nitroimidazoxazine antimycobacterial agent, presents a valuable option for the treatment of adults with pulmonary extensively drug-resistant (XDR) tuberculosis (TB) or treatment-intolerant or nonresponsive multidrug-resistant (MDR)-TB when used as part of an all-oral combination regimen with bedaquiline and linezolid
- Pretomanid with bedaquiline and linezolid for drug-resistant TB: a . . .
Pretomanid (Pa, PTM), a nitro-imidazooxazine that blocks mycobacterial cell wall production and increases nitric oxide release, was recently approved by the US Food and Drug Administration (US FDA) as part of a combination regimen BPaL (with BDQ and LZD) for the treatment of adults with pulmonary XDR-TB, or treatment-intolerant or non-responsive
- Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for . . .
Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis Lancet Respir Med 2024 Feb;12(2):e5-e6 doi: 10 1016 S2213-2600(23)00426-5
- Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for . . .
In December, 2022, based on results from a subsequent international randomised trial, 2 WHO recommended an alternative regimen—bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM)—for all patients with multidrug-resistant tuberculosis without fluoroquinolone resistance 3 Here we present data from all patients reported to the CDC as
- Contribution of Pretomanid to Novel Regimens Containing Bedaquiline . . .
The combination of bedaquiline (BDQ), pretomanid (PMD), moxifloxacin (MXF), and PZA (regimen abbreviated as BPaMZ) had bactericidal and sterilizing activity superior to that of RIF INH PZA in a murine model of TB, shortening the duration of treatment required to prevent relapse by 2 5 to 3 5months (4) In the subsequent phase 2 NC-005
- Contribution of Pretomanid to Novel Regimens Containing Bedaquiline . . .
Novel regimens combining bedaquiline and pretomanid with either linezolid (BPaL regimen) or moxifloxacin and pyrazinamide (BPaMZ regimen) shorten the treatment duration needed to cure tuberculosis (TB) in BALB c mice compared to that of the first-line regimen and have yielded promising results in
- Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis
Background: The bedaquiline-pretomanid-linezolid regimen has been reported to have 90% efficacy against highly drug-resistant tuberculosis, but the incidence of adverse events with 1200 mg of linezolid daily has been high The appropriate dose of linezolid and duration of treatment with this agent to minimize toxic effects while maintaining
|
|